Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
TeGenero felled by test fiasco
July 10, 2006
| A version of this story appeared in
Volume 84, Issue 28
TeGenero, the German firm whose monoclonal antibody drug TGN1412 was involved in a disastrous Phase I trial, has filed for bankruptcy. The tests, conducted in March by Parexel International, resulted in near-fatal side effects for six British volunteers. The drug was intended to fight illnesses such as leukemia, rheumatoid arthritis, and multiple sclerosis by modulating the immune system. According to TeGenero, the incident has "made it impossible to attract the investment necessary for the company to continue operations."
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter